Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus Immunochemotherapy in Metastatic ESCC
NCT05978193Phase 2Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Jan 2023
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by Shanghai Chest Hospital. Primary endpoints: Progression-Free Survival at 36 months and Safety and Feasibility of the Combined Regimen. Started Jan 2023; status: recruiting.
02
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05978193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05978193.